Page last updated: 2024-09-05

erlotinib hydrochloride and 10-propargyl-10-deazaaminopterin

erlotinib hydrochloride has been researched along with 10-propargyl-10-deazaaminopterin in 1 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (10-propargyl-10-deazaaminopterin)	Trials (10-propargyl-10-deazaaminopterin)	Recent Studies (post-2010) (10-propargyl-10-deazaaminopterin)
4,353	786	3,033	119	21	85

Protein Interaction Comparison

Protein	Taxonomy	10-propargyl-10-deazaaminopterin (IC50)
Folate receptor alpha	Homo sapiens (human)	0.168
Reduced folate transporter	Homo sapiens (human)	0.0007
Proton-coupled folate transporter	Homo sapiens (human)	0.057

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albert, I; Azzoli, CG; Bodkin, D; Iannotti, NO; Jiang, PY; Juhász, E; Kelly, K; Koutsoukos, T; Patel, JD; Pereira, JR; Weems, G; Zatloukal, P	1

Trials

1 trial(s) available for erlotinib hydrochloride and 10-propargyl-10-deazaaminopterin

Article	Year
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States	2012

Article

Year

Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:6

Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States

2012